Publications by authors named "Shengxiong Zhu"
Front Immunol
September 2024
Article Synopsis
- - High levels of anti-drug antibodies (ADA) against adalimumab can lead to reduced drug effectiveness and clinical issues, prompting the need for better testing methods since traditional assays have limitations in sensitivity and drug tolerance.
- - An innovative immunoassay platform was developed and tested on 49 patients with ankylosing spondylitis, revealing that 90% developed persistent ADA within 24 weeks, which affected drug clearance and disease relapse.
- - The findings suggested a significant relationship between ADA levels and drug clearance, highlighting a potential ADA threshold of 10 for clinical application, with IgG being the main type of ADA observed.
